Bronte Kolar
| Brontë Kolar | |
| Occupation | Entrepreneur; engineer |
|---|---|
| Known for | Zeon Systems, AI-native trucking TMS |
| Education | UC Berkeley College of Engineering; Delft University of Technology |
Brontë Kolar is an American entrepreneur, engineer, and computational biologist who is the co-founder and CEO of Zeon Systems, a company developing an AI-native transportation management system (TMS) for the trucking industry.[1] Prior to founding Zeon Systems, she worked in computational biology and bioinformatics and contributed to peer-reviewed research published in Science Translational Medicine. The company is based in San Francisco, California.
Education
Kolar studied at the Delft University of Technology in the Netherlands and at the University of California, Berkeley College of Engineering, where she earned a Master of Engineering degree in bioengineering in 2023.[2] While at Berkeley, she served as a graduate student researcher and worked as a graduate student instructor for a course on human genome, environment, and public health.
Career
Prior to founding Zeon Systems, Kolar worked in computational biology and bioinformatics. In 2023, she held a position as an associate scientist (computational) at Brightseed, a phytochemical AI biotech company. She subsequently joined LatchBio, a bioinformatics platform company based in San Francisco, where she worked as a bioinformatics engineer from 2023 to 2024 and was promoted to lead bioinformatics engineer, a role she held from 2024 to 2025.[3] During her time at LatchBio, Kolar co-authored a technical blog post on engineering plastic-degrading enzymes and PCSK9 binders using protein AI tools, exploring the application of machine learning methods to protein engineering.[4]
Also while affiliated with LatchBio, Kolar contributed as a co-author to a peer-reviewed study published in Science Translational Medicine in 2025. The paper, titled "Chimeric antigen receptor T cells against the IGHV4-34 B cell marker," appeared in volume 18, issue 835 of the journal and examined the development of CAR T-cell therapies targeting the IGHV4-34 marker expressed on certain B cells, with potential implications for the treatment of B-cell malignancies.[5] Her affiliation on that publication is listed as LatchBio, San Francisco, California.
In 2025, Kolar co-founded Zeon Systems and became its CEO. The company builds an AI-native trucking transportation management system, applying artificial intelligence to logistics and freight management operations.[6] The transition from computational biology and bioinformatics to AI-driven logistics reflects her broader focus on applying machine learning and data engineering methods to complex operational problems.
Publications
- Kolar B, et al. "Chimeric antigen receptor T cells against the IGHV4-34 B cell marker." Science Translational Medicine, vol. 18, no. 835 (2025). Template:Doi
References
- ↑ "Bronte Kolar". 'Crunchbase}'. Retrieved 2026-03-19.
- ↑ "Brontë Kolar, MEng '23 (BioE): "Women have a place in STEM."". 'University of California, Berkeley}'. Retrieved 2026-03-19.
- ↑ "Brontë Kolar". 'RocketReach}'. Retrieved 2026-03-19.
- ↑ "Engineering Plastic-Degrading Enzymes and PCSK9 Binders with Protein AI Tools". 'LatchBio}'. Retrieved 2026-03-19.
- ↑ "Chimeric antigen receptor T cells against the IGHV4-34 B cell marker".Template:Journal.18(835). doi:10.1126/scitranslmed.adr9382.
- ↑ "Zeon Systems". 'Zeon Systems}'. Retrieved 2026-03-19.